COSCIENS Biopharma Inc. (CSCIF)
OTCMKTS · Delayed Price · Currency is USD
2.050
-0.190 (-8.48%)
At close: Nov 17, 2025
COSCIENS Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 9.05 | 9.59 | 7.14 | 14.57 | 5.26 | 3.65 | Upgrade | |
Revenue Growth (YoY) | -3.97% | 34.22% | -50.98% | 177.03% | 44.03% | 586.47% | Upgrade |
Cost of Revenue | 5.04 | 4.86 | 4.21 | 6.02 | 0.09 | 2.32 | Upgrade |
Gross Profit | 4.01 | 4.73 | 2.94 | 8.56 | 5.17 | 1.34 | Upgrade |
Selling, General & Admin | 6.33 | 6.37 | 5.53 | 2.87 | 7.27 | 5.89 | Upgrade |
Research & Development | 5.26 | 8.3 | 2.04 | 1.37 | 6.57 | 1.51 | Upgrade |
Other Operating Expenses | - | - | - | - | - | -0.14 | Upgrade |
Operating Expenses | 11.59 | 14.67 | 7.57 | 4.24 | 13.84 | 7.26 | Upgrade |
Operating Income | -7.58 | -9.94 | -4.63 | 4.32 | -8.67 | -5.93 | Upgrade |
Interest Expense | -0.16 | -0.13 | -0.14 | -0.14 | -0.01 | -0 | Upgrade |
Interest & Investment Income | 0.39 | 0.44 | 0.06 | 0.15 | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.11 | 0.05 | -0.02 | 0.21 | 0.22 | 0.57 | Upgrade |
Other Non Operating Income (Expenses) | 0.75 | 2.7 | 0.36 | -0.01 | -0.01 | 0.42 | Upgrade |
EBT Excluding Unusual Items | -6.71 | -6.89 | -4.37 | 4.53 | -8.48 | -4.94 | Upgrade |
Merger & Restructuring Charges | -4.08 | -4.08 | - | - | - | - | Upgrade |
Asset Writedown | -3.04 | -4.26 | - | - | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.22 | Upgrade |
Pretax Income | -13.82 | -15.23 | -4.37 | 4.53 | -8.48 | -4.72 | Upgrade |
Income Tax Expense | 1.08 | 0.08 | -0.89 | 1.08 | -0.11 | 0.4 | Upgrade |
Earnings From Continuing Operations | -14.91 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade |
Net Income | -14.91 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade |
Net Income to Common | -14.91 | -15.31 | -3.49 | 3.45 | -8.37 | -5.12 | Upgrade |
Shares Outstanding (Basic) | 3 | 3 | 2 | 2 | 1 | 0 | Upgrade |
Shares Outstanding (Diluted) | 3 | 3 | 2 | 2 | 1 | 0 | Upgrade |
Shares Change (YoY) | 30.54% | 39.74% | -0.39% | 61.37% | 179.74% | 134.83% | Upgrade |
EPS (Basic) | -4.73 | -5.93 | -1.89 | 1.87 | -7.28 | -12.46 | Upgrade |
EPS (Diluted) | -4.73 | -5.93 | -1.89 | 1.86 | -7.28 | -12.46 | Upgrade |
Free Cash Flow | -10.97 | -15.73 | -3.3 | 4.93 | -8.61 | -4.13 | Upgrade |
Free Cash Flow Per Share | -3.48 | -6.09 | -1.79 | 2.66 | -7.49 | -10.05 | Upgrade |
Gross Margin | 44.30% | 49.33% | 41.13% | 58.71% | 98.29% | 36.55% | Upgrade |
Operating Margin | -83.74% | -103.70% | -64.81% | 29.65% | -164.85% | -162.24% | Upgrade |
Profit Margin | -164.63% | -159.69% | -48.79% | 23.66% | -159.09% | -140.14% | Upgrade |
Free Cash Flow Margin | -121.17% | -164.07% | -46.26% | 33.80% | -163.71% | -113.06% | Upgrade |
EBITDA | -6.63 | -8.68 | -3.47 | 5.79 | -8.53 | -5.69 | Upgrade |
EBITDA Margin | -73.27% | -90.52% | -48.62% | 39.72% | -162.09% | -155.89% | Upgrade |
D&A For EBITDA | 0.95 | 1.26 | 1.16 | 1.47 | 0.15 | 0.23 | Upgrade |
EBIT | -7.58 | -9.94 | -4.63 | 4.32 | -8.67 | -5.93 | Upgrade |
EBIT Margin | -83.74% | -103.70% | -64.81% | 29.65% | -164.85% | -162.24% | Upgrade |
Effective Tax Rate | - | - | - | 23.85% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.